Skip to main content

REVIEW article

Front. Cell Dev. Biol.
Sec. Molecular and Cellular Pathology
Volume 12 - 2024 | doi: 10.3389/fcell.2024.1473616
This article is part of the Research Topic Vascular- and Immuno-Metabolism as Drivers of Cardiovascular Disease: Insights Obtained from Omics Approaches View all 7 articles

(Multi-) Omics studies of ILC2s in inflammation and metabolic diseases

Provisionally accepted
Maria Kral Maria Kral 1,2*Emiel Van Der Vorst Emiel Van Der Vorst 1,3,4Christian Weber Christian Weber 1,2,5,6Yvonne Döring Yvonne Döring 1,2,7,8*
  • 1 Institute for Cardiovascular Prevention, LMU Munich University Hospital, Munich, Germany
  • 2 Partner site Munich Heart Alliance,DZHK, (German Centre for Cardiovascular Research), Munich, Bavaria, Germany
  • 3 Aachen-Maastricht Institute for CardioRenal Disease (AMICARE), Interdisciplinary Center for Clinical Research (IZKF), Aachen, Germany
  • 4 Institute for Molecular Cardiovascular Research, University Hospital RWTH Aachen, Aachen, Germany
  • 5 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands, Maastrich, Netherlands
  • 6 Munich Cluster of Systems Neurology (SyNergy), Munich, Bavaria, Germany
  • 7 Department of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, Bern, Switzerland
  • 8 Department of Biomedical Research, Faculty of Medicine, University of Bern, Bern, Bern, Switzerland

The final, formatted version of the article will be published soon.

    Type 2 innate lymphoid cells (ILC2s) have emerged as pivotal regulators in the pathogenesis of diseases, with their roles in inflammation, metabolism, and tissue homeostasis becoming increasingly recognized. This review provides an overview of the current understanding of ILC2s in inflammation and metabolic disorders, including their functional contributions. Moreover, we will discuss how these cells adapt their metabolic processes to support their function and survival and how their metabolic requirements change under different physiological and pathological conditions. Lastly, we will review recent omics studies that have provided insights into the molecular and cellular characteristics of ILC2s. This includes transcriptomic, proteomic, and metabolomic analyses that have elucidated the gene expression profiles, protein interactions, and metabolic networks, respectively, associated with ILC2s. These studies have advanced our understanding of the functional diversity of ILC2s and their involvement in metabolic disease.

    Keywords: ILC2, Metabolism, Metabolic Diseases, omics, single-cell RNA sequencing

    Received: 31 Jul 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 Kral, Van Der Vorst, Weber and Döring. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Maria Kral, Institute for Cardiovascular Prevention, LMU Munich University Hospital, Munich, Germany
    Yvonne Döring, Institute for Cardiovascular Prevention, LMU Munich University Hospital, Munich, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.